Publication: Effect of melatonin on the cardiotoxicity of doxorubicin
Authors
Balli, E. ; Mete, U.O. ; Tuli, A. ; Tap, O. ; Kaya, M.
item.page.secondaryauthor
item.page.director
Publisher
Murcia : F. Hernández
publication.page.editor
publication.page.department
DOI
item.page.type
info:eu-repo/semantics/article
Description
Abstract
This study was designed to investigate the
preventive effect of melatonin on doxorubicin’s most
important side effect, cardiotoxicity. Forty male albino
Wistar rats were utilized and the rats were divided into
five groups: group I, 0.9 % NaCl for 4 days; group II,
doxorubicin 3 mg/kg/day for 4 days; group III, 2.5 %
ethanol for 15 days; group IV, melatonin 6 mg/kg/day
for 15 days; and group V, a doxorubicin and melatonin
combination were administered intraperitoneally. At the
end of the experiment, tissue samples obtained from the
cardiac muscle of the left ventricle of the rats were
processed for measurement of malondialdehyde and for
electron microscopic examination. Malondialdehyde, a
product of lipid peroxidation, was found to be
significantly higher in the doxorubicin group. However,
in the doxorubicin and melatonin combination group the
level of malondialdehyde was decreased statistical
significant. The histological examination revealed
destruction of myofibrils, disorganization of sarcomeres,
mitochondrial degeneration and formation of giant
mitochondria and lipid accumulation in the doxorubicin
group. Also, accumulation of filamentous structures in
the sarcoplasma in some of the cells, structural changes
in capillaries and an increase in collagen fibers forming
bundles were observed. When melatonin was added to
the doxorubicin treatment all structural changes were
reduced. The cardiotoxic side effect of doxorubicin used
as a chemotherapeutic agent and was probably developed as a result of supression of the antioxidant
system and lipid peroxidation. Therefore, it could be
assumed that the addition of melatonin in the treatment
of doxorubicin could prevent the cardiotoxicity of
doxorubicin.
publication.page.subject
Citation
item.page.embargo
Ir a EstadĂsticas
Sin licencia Creative Commons.